Key Takeaways
- • Yale University and Biohaven Therapeutics have jointly requested $23.1 million in attorney fees following a $4 million trial verdict on trade secrets and contract breach claims, representing a 5.75x multiplier on the award.
- • Both entities are simultaneously pursuing a motion for a new trial to challenge the damages determination on the underlying trade secrets and contract breach claims, signaling potential dissatisfaction with the jury's award level.
- • The request includes $2 million each in exemplary damages for both Yale and Biohaven, indicating findings of willful or aggravated misconduct by the opposing party.
- • The case involves intellectual property protection in the pharmaceutical/therapeutics sector, with trade secret misappropriation as a central dispute.
Summary
Yale University and Biohaven Therapeutics have filed a substantial attorney fee petition seeking $23.1 million in combined legal costs following their trial victory on September 22, 2026. The request comes after a jury awarded them $4 million in damages on claims involving trade secrets and contract breach. The fee request significantly exceeds the trial verdict, suggesting substantial litigation expenses over what appears to be a complex intellectual property dispute in the therapeutics sector.
In addition to the attorney fee claim, both entities are pursuing a motion for a new trial focused specifically on the damages component of the trade secrets and contract breach claims. This dual-track approach—simultaneously seeking to enforce the current verdict while challenging its adequacy—indicates that Yale and Biohaven may view the jury's $4 million award as insufficient compensation for losses sustained or breaches established during trial.
The exemplary damages component of the petition—$2 million each for Yale and Biohaven—suggests the court or jury found evidence of willful, malicious, or otherwise aggravated conduct by the opposing party, elevating the case beyond straightforward contractual or negligent misappropriation into the territory of intentional wrongdoing. Combined with the magnitude of the attorney fee request, this positioning reflects a significant enforcement action in pharmaceutical intellectual property litigation.
The outcome of both the fee petition and new trial motion will have material implications for cost allocation in complex IP disputes and may set precedent for attorney fee awards in trade secret litigation within the life sciences sector. For institutional investors and family offices with stakes in therapeutics or pharmaceutical intellectual property portfolios, this case underscores the escalating cost and complexity of defending proprietary information and enforcing contractual protections in competitive biotech environments.
In addition to the attorney fee claim, both entities are pursuing a motion for a new trial focused specifically on the damages component of the trade secrets and contract breach claims. This dual-track approach—simultaneously seeking to enforce the current verdict while challenging its adequacy—indicates that Yale and Biohaven may view the jury's $4 million award as insufficient compensation for losses sustained or breaches established during trial.
The exemplary damages component of the petition—$2 million each for Yale and Biohaven—suggests the court or jury found evidence of willful, malicious, or otherwise aggravated conduct by the opposing party, elevating the case beyond straightforward contractual or negligent misappropriation into the territory of intentional wrongdoing. Combined with the magnitude of the attorney fee request, this positioning reflects a significant enforcement action in pharmaceutical intellectual property litigation.
The outcome of both the fee petition and new trial motion will have material implications for cost allocation in complex IP disputes and may set precedent for attorney fee awards in trade secret litigation within the life sciences sector. For institutional investors and family offices with stakes in therapeutics or pharmaceutical intellectual property portfolios, this case underscores the escalating cost and complexity of defending proprietary information and enforcing contractual protections in competitive biotech environments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.